856676-23-8 Usage
Description
Unii-4bmh7izt98, also known as Choline fenofibrate, is a lipid-regulating agent available as a white solid in delayed-release capsules for oral administration. It is primarily used in combination with a statin to reduce triglycerides (TG) and increase high-density lipoprotein cholesterol (HDL-C) in patients with mixed dyslipidemia and coronary heart disease (CHD) or a CHD-risk equivalent. Additionally, it is used as monotherapy in patients with severe hypertriglyceridemia and primary hyperlipidemia or mixed dyslipidemia to reduce elevated LDL-C, total cholesterol, TG, apolipoprotein B, and to increase HDL-C. Choline fenofibrate is the salt formulation of fenofibric acid, which is also the active metabolite of fenofibrate (Tricor), previously marketed for the treatment of hypercholesterolemia and hypertriglyceridemia.
Uses
Used in Pharmaceutical Industry:
Unii-4bmh7izt98 is used as a lipid-regulating agent for the treatment of mixed dyslipidemia, coronary heart disease, and severe hypertriglyceridemia. It is used in combination with statins to achieve optimal lipid levels in patients who are on statin therapy to reach their low-density lipoprotein cholesterol (LDL-C) goal.
Unii-4bmh7izt98 is used as monotherapy for the treatment of severe hypertriglyceridemia to reduce triglyceride levels and in patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated LDL-C, total cholesterol, TG, apolipoprotein B, and to increase HDL-C.
The primary mode of action of Unii-4bmh7izt98 is through the activation of the nuclear transcription factor PPARa, predominantly expressed in tissues that metabolize fatty acids, such as the liver, kidney, heart, and muscle. On activation by binding of the fibrate, PPARa binds as heterodimers with retinoid X receptor (RXR), which subsequently recognizes and binds to specific PPARa-response elements leading to modulation of expression of the target genes. In particular, the activity of lipoprotein lipase is increased, and synthesis of apolipoprotein C-III is decreased, which together enhance the clearance of circulating TG-rich lipoproteins. The resulting fall in TG produces an alteration in the size and composition of LDL from small dense particles to large buoyant particles, which have a greater affinity for cholesterol receptors and are catabolized rapidly.
Unii-4bmh7izt98 is contraindicated in patients with severe renal impairment. It is marketed under the brand name TriLipix.
Originator
Abbott (United States)
Side effects
The most common adverse reactions observed with the use of fenofibric acid alone or in combination with a statin are headache, back pain, nasopharyngitis, nausea, myalgia, diarrhea, and upper respiratory tract infection.
Synthesis
Choline To Market, To Market 2008 enofibrate is chemically derived from p-anisole in four steps through Friedel Crafts acylation with p-chlorobenzoyl chloride to the corresponding benzophenone derivative, followed by methyl ether cleavage with hydrogen bromide, alkylation of the phenolic hydroxyl group with 2-bromo-2-methylpropanoic acid using sodium hydroxide, and finally salt formation with choline.
Check Digit Verification of cas no
The CAS Registry Mumber 856676-23-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,6,6,7 and 6 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 856676-23:
(8*8)+(7*5)+(6*6)+(5*6)+(4*7)+(3*6)+(2*2)+(1*3)=218
218 % 10 = 8
So 856676-23-8 is a valid CAS Registry Number.
InChI:InChI=1/C17H15ClO4.C5H14NO/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11;1-6(2,3)4-5-7/h3-10H,1-2H3,(H,20,21);7H,4-5H2,1-3H3/q;+1/p-1
856676-23-8Relevant articles and documents
Phenoxy aromatic acid with cyclopropyl and pharmaceutically acceptable salt thereof as well as preparation method and application thereof
-
, (2021/07/17)
The invention provides phenoxy aromatic acid with cyclopropyl, a preparation method of the phenoxy aromatic acid, pharmaceutically acceptable salt of the phenoxy aromatic acid with cyclopropyl and a preparation method of the pharmaceutically acceptable salt, and further provides dosage forms of the phenoxy aromatic acid with cyclopropyl and the pharmaceutically acceptable salt of the phenoxy aromatic acid with cyclopropyl. The invention also discloses application of the compound in medicines for treating hyperlipidemia diseases. The compound provided by the invention has a relatively good blood fat reducing drug effect, so that the compound has a very good application prospect.
Interesting morphological behavior of organic salt choline fenofibrate: Effect of supersaturation and polymeric impurity
Bordawekar, Shailendra,Kuvadia, Zubin,Dandekar, Preshit,Mukherjee, Samrat,Doherty, Michael
, p. 3800 - 3812 (2014/08/18)
Crystal habit of drug molecules can have significant influence on the processing and performance of pharmaceutical products. During the development of Trilipix, a pharmaceutical product used for the treatment of mixed dyslipidemia, several crystal habits were observed for the active ingredient choline fenofibrate. The dissolution and performance of the drug product were not impacted by changes in crystal habit of the active ingredient due to high solubility of the drug. However, the formulation process was impacted by variations in crystal habit of the active ingredient, requiring robust control of the crystal habit. The crystal habit was greatly influenced by supersaturation during crystallization from a mixed solvent system comprising methanol and isopropanol. In addition to supersaturation, trace levels of a polymeric impurity in the starting material fenofibrate had a detrimental effect on the crystal habit. This article discusses the effects of these factors on the crystal habit of choline fenofibrate and the design of a crystallization process to deliver the target crystal habit, most suited to the formulation process. The article also provides preliminary mechanistic insights into the crystal habit of this organic salt using an extension of the spiral growth model for morphology prediction of organic molecular crystals. An attempt is made to explain the effect of supersaturation and impurity on the crystal habit of choline fenofibrate using the concepts of stability of surfaces, building units, periodic bond chain theory, and the spiral growth model.
AN IMPROVED PROCESS FOR THE PREPARATION OF CHOLINE SALT OF FENOFIBRIC ACID AND ITS NOVEL POLYMORPH
-
Page/Page column 7, (2010/08/09)
The present invention relates to an improved process for the preparation of choline salt of fenofibric acid corresponding to formula (I). The present invention also provides crystalline polymorphic form of choline salt of fenofibric acid corresponding to formula (I) designated as form A.